The combination of intestinal inhibition of FXR and prebiotic supplementation may constitute a promising approach in the management of metabolic disorders such as type 2 diabetes and their complications such as NAFLD and cardiovascular diseases. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.